SRR934848
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.71747700394218
- age_years
- 35
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.498
- WNT_BETA_CATENIN_SIGNALING+0.338
- MYC_TARGETS_V1+0.325
- INTERFERON_GAMMA_RESPONSE+0.318
- TGF_BETA_SIGNALING+0.293
- MITOTIC_SPINDLE+0.290
- CHOLESTEROL_HOMEOSTASIS+0.265
- ANDROGEN_RESPONSE+0.238
- MYC_TARGETS_V2+0.231
- G2M_CHECKPOINT+0.222
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.533
- MYOGENESIS-0.354
- KRAS_SIGNALING_DN-0.331
- COAGULATION-0.253
- SPERMATOGENESIS-0.243
- ESTROGEN_RESPONSE_LATE-0.234
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.209
- TNFA_SIGNALING_VIA_NFKB-0.158
- INFLAMMATORY_RESPONSE-0.150
- HYPOXIA-0.148
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E35A6AA5-331F-489B-8CE1-9D0BC4CDE119 | — | — | 0.871 |
| 2 | SRR934865 | — | — | 0.869 |
| 3 | SRR934808 | — | — | 0.846 |
| 4 | E55DA565-D03C-46BF-A498-0677AFA19D74 | — | — | 0.828 |
| 5 | SRR934799 | — | — | 0.825 |
| 6 | 8D39DD37-3B56-4788-B256-D924EBF2BD21 | — | — | 0.821 |
| 7 | SRR934775 | — | — | 0.815 |
| 8 | EFEDAFE3-FF81-47ED-97F6-1193EA375D77 | — | — | 0.810 |
| 9 | SRR934914 | — | — | 0.801 |
| 10 | SRR934795 | — | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.498 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.338 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.325 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.318 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.293 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.265 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.238 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.231 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.222 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.222 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.208 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.188 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.178 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.163 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.152 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.102 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.096 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.074 | Inavolisib | — uncovered |